SB-509: Phase II started

SGMO began a double-blind, U.S. Phase II trial in about 100 patients.

Read the full 124 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE